SIOX - Sio Gene Therapies: Risk-On Gene Therapy Prospect May Offer Value For Money

• Sio used to be called Axovant - an unsuccessful biotech that attempted to bring several therapies to market, including an Alzheimer's treatment.
• Axovant burned through investors' cash after raising a >$300m IPO in 2015, before abandoning all of its projects and handing control to current CEO Pavan Cheruvu.
• Cheruvu has pivoted Axovant into a gene therapy specialist with a two therapies targeting Gangliosidosis - a rare but deadly genetic disease - and one targeting Parkinson's.
• Some positive data from early trials of lead candidate AXO-AAV-GM1 have lifted the share price somewhat, but shares are still priced very low.
• Any investment in Sio Gene would be highly speculative, but the work completed by the CEO to date seems impressive and gene therapy stocks can realize massive gains on breakthrough data.

For further details see: